OX40 Bioassay

Immunostimulatory receptors are emerging as promising targets for cancer immunotherapies. As a leading antibody service provider, Creative Biolabs has established a panel of assays for screening of safer and more efficient antibodies against various immune checkpoints, including both co-inhibitory and co-stimulatory molecules. OX40 is one of the co-stimulatory molecules that have been targeted for tumor treatment. Here, we present the OX40 assay as an attractive method for assessing the potency and mechanism of action of anti-OX40 antibodies.

Introduction to OX40

OX40 (CD134), a member of the tumor necrosis factor receptor (TNFR) superfamily, is a co-stimulatory molecule. Structurally, this glycoprotein contains a cytoplasmic tail, a transmembrane domain, and an extracellular region. OX40 is predominantly expressed by T cells. It is transiently expressed by human CD4⁺ and CD8⁺ T cells following T cell receptor (TCR) stimulation. The ligand for OX40, OX40L (CD252), is classically expressed on antigen-presenting cells (APCs). Binding of OX40 to its ligand modulates T cell activation and T cell effector function. The OX40-OX40L pathway has been targeted in tumor immunotherapy. Anti-OX40 agonistic monoclonal antibodies and OX40L-Fc fusion proteins are currently tested in early phase cancer clinical trials. They have been reported to increase antitumor immunity and improve tumor-free survival. Besides, clinical trials with OX40 agonists are ongoing in patients with tumors, with both monotherapy and combination therapy included.

Fig. 1 The OX40L-OX40 axis stimulates the proliferation of effector Th1 and Th2 cells.¹

OX40 Bioassay Provided by Creative Biolabs

To aid in the binding & interaction characterization of anti-immune checkpoint antibody, Creative Biolabs offers a broad and integrated portfolio of immune checkpoint interaction analysis services. Especially, we offer immune checkpoint-targeted reporter gene assays to investigate the potency and mechanism of action of your antibody candidates. Our assays cover the most popular immune checkpoints. These assays overcome the limitations of primary cell-based assays, including complex assay protocols, unqualified assay reagents, and dependent on donor primary cells.

Advantages of Our Services

• Excellent expert team to offer real-time technical guidance
• Advanced assay platforms to promote the data output
• Timely data feedback to facilitate the process of your project

Trending Products

Creative Biolabs offers a comprehensive selection of OX40 bioassay kits tailored for characterizing OX40 and advancing the development of novel antibodies. Moreover, we also have the ability to construct OX40 reporter cell lines. Explore our specific OX40 bioassay kits via the offered link to get more information.

Published Data

Researchers have developed a novel human anti-OX40 antibody, which displays enhanced antibody-dependent cellular cytotoxicity (ADCC) due to fucose deletion, resulting in improved Treg depletion activity and superior to other anti-OX40 antibodies. This study aims to explore the functionalities of human anti-OX40 antibody and compare its effects with an OX40 agonistic antibody (PF-04518600) using a variety of assays.

Fig.2 Detection of T cell activation function of human anti-OX40 antibody using the NF-kB luciferase reporter assay.²

Fig.3 Examination of ADCC activity of human anti-OX40 antibody using the NFAT luciferase reporter assay.²

Moreover, Creative Biolabs also offers professional immune checkpoint functional assays, providing measurements of T cell proliferation, T cell cytotoxicity, and cytokine release. Creative Biolabs is professional in designing custom assay protocols to meet all kinds of expectations and requirements. We are happy to work with you step by step so as to ensure that most satisfactory results can be acquired. If you are interested in our services, please contact us or send us an inquiry.

Reference

1. Furue, Masutaka, and Mihoko Furue. "OX40L–OX40 signaling in atopic dermatitis." Journal of Clinical Medicine 10.12 (2021): 2578.
   Distributed under Open Access License CC BY 4.0, without modification.
2. Liang, Shizhong, et al. "BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy." Frontiers in Oncology 13 (2023).
   Distributed under Open Access License CC BY 4.0. The original images Figure 2 and Figure 3 were modified by extracting and using part B, and the titles were changed to "Detection of T cell activation function of human anti-OX40 antibody using the NF-kB luciferase reporter assay" and "Examination of ADCC activity of human anti-OX40 antibody using the NFAT luciferase reporter assay", respectively.

For Research Use Only.